← Leaderboards
Gareth John Morgan
Tezcat Laboratories Llc
$5,963,595
Attributed
$6,484,935
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–25$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,484,935 · 3
By mechanism
R01$6,085,058 · 2
R41$399,877 · 1
Top collaborators
- Dafna Bar-Sagi1 shared
- Elizabeth E Brown1 shared
- Craig Patrick Ramirez1 shared
Most similar at Tezcat Laboratories Llc
Same institution · by research overlap
- Craig Patrick Ramirez$3,645,136
Others in their field
Other Emerging Leaders on “Malignant Neoplasms”
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
- Leonard Freedmand · Leidos Biomedical Research, Inc.$108,968,336
- Beverly Hayes · Leidos Biomedical Research, Inc.$98,336,166
- Martha Hering · Westat, Inc.$57,098,843
Research focus
Malignant NeoplasmsIncidenceBiologicalMultiple MyelomaUniversitiesWhole GenomeMonoclonal Gammopathy Of Uncertain SignificanceMediatingNew YorkMutationT Cell ResponseT-LymphocyteGenomicsBone MarrowEnvironmental ExposureEtiologyEventGenome SequencingImmune ResponseResponseAntigensCross-Sectional StudiesEarly OnsetChronology
Grant awards (7)
Mutographs differentiating the inheritance and temporal onset of multiple myeloma$1,127,014
R01 · FY2025 · CA · contact PI
Role of Disadvantage, Mutographs and T Cell Immunity on MGUS in African Americans$509,510
R01 · FY2025 · CA
Mutographs differentiating the racial and temporal incidence of multiple myeloma$1,054,153
R01 · FY2024 · CA · contact PI
Mutographs differentiating the racial and temporal incidence of multiple myeloma$1,070,373
R01 · FY2023 · CA · contact PI
Mutographs differentiating the racial and temporal incidence of multiple myeloma$1,089,218
R01 · FY2022 · CA · contact PI
Mutographs differentiating the racial and temporal incidence of multiple myeloma$1,234,790
R01 · FY2021 · CA · contact PI
A novel monobody-drug conjugate to treat mutant Ras multiple myeloma$399,877
R41 · FY2020 · CA